Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)

NCT00096954 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00096954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00096954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2006
Completion date
September 30, 2010
Enrollment
333 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma